clinical trials – The Milli Chronicle

Thursday, April 9, 2026

Latest:

Fuel Shortages and Price Surge Trigger Reverse Migration from Delhi as Low-Income Workers Struggle to Access Food
Experimental CAR-T Therapy Induces Remission in Patient with Multiple Autoimmune Disorders
Global Calls Grow to Extend US-Iran Ceasefire to Lebanon After Deadly Strikes
Report Alleges Ethiopian Base Aided Sudan Paramilitary Operations
Israel Strikes Lebanon Again as Death Toll Surges, Ceasefire at Risk

Factual Version of a Story

NewsDesk MC April 9, 2026April 9, 2026 AIHA, antiphospholipid syndrome, APS, autoimmune diseases, autoimmune haemolytic anaemia, B-cells, blood disorders, CAR-T therapy, CD19 therapy, cell therapy, clinical trials, experimental medicine, Germany healthcare, immune system reset, immune thrombocytopenia, immunotherapy, ITP, lupus research, Manchester University NHS Foundation Trust, multiple sclerosis, rare diseases, T-cells, treatment resistant diseases, University Hospital Erlangen

Experimental CAR-T Therapy Induces Remission in Patient with Multiple Autoimmune Disorders

“The prolonged response off normal therapy suggests there has been an immune reset.” A 47-year-old woman with three severe autoimmune

Featured News World

NewsDesk MC November 4, 2025 Center for Drug Evaluation and Research, clinical trials, drug approval process, drug safety, ethical governance, FDA ethics, FDA leadership change, FDA modernization, FDA reform, Food and Drug Administration, global drug safety, health policy, healthcare transparency, medical innovation, medical research, pharmaceutical innovation, pharmaceutical regulation, public health, Robert F. Kennedy Jr., U.S. health agencies, US FDA

US FDA’s Drug Division Undergoes Leadership Transition to Strengthen Integrity and Innovation

The U.S. Food and Drug Administration begins a new chapter in its drug evaluation and research division, focusing on ethics,

Latest Middle East and North Africa News

NewsDesk MC October 9, 2025October 9, 2025 advanced medical treatment, ALS clinical outcomes, ALS drug registration, ALS medication Saudi Arabia, ALS treatment, amyotrophic lateral sclerosis, antisense therapy, clinical trials, Health Sector Transformation Program, innovative therapies, Kingdom healthcare development, nerve cell protection, neurodegenerative disease, neurofilament reduction, orphan drugs, patient access, pharmaceutical innovation, protein misfolding therapy, Qalsody approval, rare disease therapy, rare genetic disease treatment, Saudi Arabia healthcare, Saudi FDA, Saudi medical innovation, Saudi patient care, Saudi rare disease patients, SOD1 gene, SOD1 protein reduction., Tofersen, vision 2030

Saudi FDA Approves Qalsody for ALS, Pioneering New Hope for Rare Disease Patients

Riyadh – In a landmark decision for rare disease treatment in Saudi Arabia, the Saudi Food and Drug Authority (SFDA)

Asia Health Latest Lifestyle News

NewsDesk MC September 25, 2025September 25, 2025 anti-obesity medication, clinical trials, diabetes and obesity treatment, diabetes medication, Eli Lilly, Eli Lilly India launch, Eli Lilly pharmaceutical update, experimental obesity drug, GLP-1 receptor agonist, GLP-1 treatment, health innovation, healthcare news India, innovative healthcare solutions, medical breakthrough India, new drug approval India, obesity management, pharmaceutical industry India, pharmaceutical launch India, weight management therapy, weight-loss pill India

Eli Lilly plans to bring experimental weight-loss pill in India

Mumbai, (Reuters) – Eli Lilly (LLY.N),plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on